Orchard Therapeutics announces pricing of its initial public offering

31 October 2018

UCLB spinout Orchard Therapeutics has announced the pricing of its initial public offering in the United States of 14,285,715 American Depositary Shares (“ASDs”) representing 14,285,715 ordinary shares at an initial public offering price of $14.00 per ADS, before underwriting discounts and commissions.

Orchard Therapeutics was founded in 2015, based on research arising from the groups of Prof. Bobby Gaspar and Prof. Adrian Thrasher, at the UCL Institute of Child Health.

Read more from this story here: Orchard Therapeutics

2018-11-05T09:52:53+00:00